10-K: GE HealthCare Reports Strong 2025 Revenue Growth Amid Tariff Headwinds

GE HealthCare Technologies Inc. reported a 4.8% increase in total revenues for 2025, reaching $20.6 billion, driven by strong performance in its PDx, Imaging, and AVS segments, despite significant tariff impacts and a decline in its PCS segment.

Summary

• Total revenues for the year ended December 31, 2025, were $20,625 million, a 4.8% increase (3.5% organically) compared to $19,672 million in 2024.
• Sales of products increased by $586 million (4.5%), and sales of services increased by $368 million (5.6%).
• Operating income rose by $138 million (5.3%) to $2,763 million, representing 13.4% of total revenues.
• Net income attributable to GE HealthCare increased by $91 million (4.6%) to $2,084 million.
• Diluted earnings per share (EPS) increased to $4.55 in 2025 from $4.34 in 2024.
• The Pharmaceutical Diagnostics (PDx) segment led growth with revenues of $2,900 million, up 15.6% (8.8% organically), driven by volume and price increases.
• Imaging segment revenues grew 4.4% to $9,245 million, and Advanced Visualization Solutions (AVS) revenues increased 4.3% to $5,354 million.
• Patient Care Solutions (PCS) segment revenues decreased 1.2% to $3,086 million, primarily due to a decline in Life Support Solutions.
• Tariffs materially impacted operating income by approximately $245 million and cash flows by approximately $285 million in 2025.
• Cash from operating activities was $1,987 million, a slight increase from $1,955 million in 2024.
• Free cash flow decreased 3.2% to $1,505 million in 2025.
• Total debt increased to $10,003 million as of December 31, 2025, from $8,951 million in 2024.
• The company authorized a $1,000 million share repurchase program on April 30, 2025, and repurchased $200 million of common stock during the year.
• GE HealthCare acquired icometrix NV for approximately $98 million upfront and the remaining 50% interest in Nihon Medi-Physics Co., Ltd. (NMP) for $271 million net cash consideration.
• An agreement to acquire Intelerad for $2,300 million in cash was announced on November 20, 2025, expected to close in the first half of 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively due to solid revenue and earnings growth, strategic acquisitions, and a strong liquidity position, despite acknowledging significant macroeconomic headwinds like tariffs and regional market pressures.

Positives

• Total revenues increased by 4.8% to $20,625 million, demonstrating overall business growth.
• Organic revenue growth of 3.5% indicates healthy underlying business performance.
• The Pharmaceutical Diagnostics (PDx) segment showed strong growth of 15.6% (8.8% organically) driven by increased volume and pricing.
• Operating income increased by 5.3% to $2,763 million, and net income attributable to GE HealthCare grew by 4.6% to $2,084 million.
• Diluted EPS improved to $4.55 in 2025 from $4.34 in 2024.
• The company authorized a $1,000 million share repurchase program and executed $200 million in repurchases, signaling confidence in its valuation and commitment to shareholder returns.
• Strategic acquisitions of icometrix and the remaining interest in NMP are expected to expand capabilities in AI-powered brain imaging analysis and radiopharmaceuticals.
• The proposed acquisition of Intelerad is anticipated to create a more comprehensive, cloud-first, and AI-enabled imaging offering.
• Cash, cash equivalents, and restricted cash increased significantly to $4,512 million, providing strong liquidity.

Negatives

• Tariffs materially impacted operating income by approximately $245 million and cash flows by approximately $285 million in 2025.
• The Patient Care Solutions (PCS) segment experienced a revenue decrease of 1.2%, primarily due to a decline in Life Support Solutions.
• Adjusted EBIT margin decreased by 100 basis points to 15.3% in 2025.
• Cost of products sold increased by 220 basis points as a percent of sales, driven by cost inflation and incremental tariffs.
• Cost of services sold increased by 90 basis points as a percent of sales, due to unfavorable mix and cost inflation, including tariffs.
• China region revenues decreased by 4.6%, reflecting continued pressure from increased local competition and Volume Based Procurement policies.
• Total debt increased to $10,003 million as of December 31, 2025, from $8,951 million in 2024.
• Non-operating benefit income decreased by $118 million, primarily due to lower expected returns on plan assets and increased interest cost.
• The company has significant postretirement benefit liabilities, with a net deficit of $4,365 million as of December 31, 2025.

Risks

• Operating in highly competitive markets, with potential for new technology, product obsolescence, and pricing pressures.
• Exposure to global geopolitical and economic instability, including trade and tariff policies, international conflicts (e.g., Ukraine and Russia), and inflationary pressures.
• Public health crises, epidemics, and pandemics could negatively impact business operations, supply chains, and demand.
• Efforts by public and private payers to control healthcare costs may lead to lower reimbursements or increased utilization controls, affecting demand and pricing.
• Inability to successfully complete strategic transactions (acquisitions, dispositions) or manage collaboration arrangements could adversely affect business strategy and expected benefits.
• Investments in cloud, edge computing, AI, and software offerings may not generate new offerings, attract customers, or yield sufficient revenue, with inherent risks of failure and regulatory challenges.
• Supply chain disruptions, inability to obtain components or raw materials, and reliance on single-source suppliers could restrict manufacturing, cause delivery delays, or increase costs.
• Increased cybersecurity requirements, vulnerabilities, threats, and sophisticated cybercrimes pose risks to systems, networks, products, services, data, and reputation.
• Inability to obtain, maintain, protect, or effectively enforce intellectual property rights, including the GE trademark, could lead to competitive disadvantages or costly litigation.
• Challenges in attracting or retaining key talent and qualified employees, or maintaining relations with employees and unions, could adversely affect business operations.
• Increasing attention to sustainability matters, including environmental, health, and safety (EH&S) issues, may impose additional costs and expose the company to new risks.
• Extensive legal and regulatory requirements governing medical devices, pharmaceutical products, anti-corruption, anti-bribery, anti-kickback, false claims, antitrust, privacy, and tax laws, with potential for significant penalties for non-compliance.
• Exposure to risks associated with product liability claims, including potential for personal injury, death, incorrect diagnosis, or product defects.
• Involvement in litigation, arbitration, and governmental proceedings, including those stemming from third-party conduct beyond control, could result in significant costs and reputational harm.
• Existing indebtedness and any additional indebtedness could limit financial flexibility and ability to fund future growth.
• Significant postretirement benefit liabilities (pension, healthcare, life insurance) have uncertain actual costs and related cash flows that could exceed current estimates.
• Changes in foreign currency exchange rates, equity prices, and interest rates, and unfavorable changes in capital markets, could adversely affect financial performance.
• Future material impairments in the value of long-lived assets, including goodwill, could negatively affect results of operations and financial condition.
• Potential conflicts of interest for directors and employees due to financial interests in GE or previous/continuing positions with GE.
• Exclusive forum provisions in the certificate of incorporation could limit stockholders' ability to obtain a favorable judicial forum.
• Certain provisions in the certificate of incorporation, bylaws, and Delaware law may discourage takeovers and limit stockholder power.

Future Outlook

GE HealthCare expects continued material impact on financial results from tariffs, with mitigation actions not fully offsetting costs. The company will continue to monitor developments in the China market, including increased competition and Volume Based Procurement policies. The Russia and Ukraine conflict is expected to continue making it burdensome and costly to serve customers in the region, with no guarantee of obtaining all necessary licenses. Geopolitical instability across multiple regions could adversely impact operations, supply chains, and logistics. The acquisition of Intelerad is expected to close in the first half of 2026. The company anticipates sufficient liquidity to meet operational needs, debt service, and investments for at least the next 12 months. In 2026, the company expects to amortize $108 million of net actuarial gain and $93 million of prior service credit from AOCI into earnings and make approximately $350 million in cash contributions to postretirement benefit plans. Restructuring initiatives are expected to incur an additional $53 million in expenses over the next 12 months. The adoption of new accounting standards (ASU 2024-03 and ASU 2025-06) is expected to increase disclosures and is being evaluated for financial statement impact, respectively.

Management Comments

• "We believe that our existing balance of Cash, cash equivalents, and restricted cash, future cash generated from operating activities, access to capital markets, and existing credit facilities will be sufficient to meet the needs of our current and ongoing operations, pay taxes due, service our existing debt, and fund investments in our business for at least the next 12 months."
• "We believe the focus of government policy in China is on expanding access to healthcare. In addition, our investments to address clinical needs, localization, and commercial infrastructure should benefit our business in China in the long term."
• "We do not expect that our mitigation actions will fully offset the additional costs or other negative impacts resulting from the tariffs."
• "The Company expects to use borrowings under the Delayed Draw Term Facility to partially fund the expected acquisition of Intelerad."

Industry Context

StockSavvy.ai notes that GE HealthCare operates in a highly competitive global medical technology industry characterized by rapid technological evolution, frequent new product introductions, and intense pricing pressures. The company's strategic focus on AI, cloud, and software solutions aligns with broader industry trends towards digital health and precision medicine. The ongoing consolidation among healthcare providers and payers, particularly in the U.S., is increasing cost-consciousness and influencing demand and reimbursement policies. Geopolitical tensions and trade protectionism, such as tariffs, are creating significant macroeconomic headwinds, impacting global supply chains and operational costs across the industry. The stringent and evolving regulatory landscape for medical devices, pharmaceuticals, and data privacy, especially concerning AI and personal health information, presents a continuous challenge for all industry participants.

Comparison to Industry Standards

• GE HealthCare competes with global and regional participants including Siemens Healthineers, Philips Healthcare, United Imaging, Mindray, and Canon in medical technology.
• In the Pharmaceutical Diagnostics segment, primary competitors include Bayer, Bracco, Guerbet, and Curium.
• The filing does not provide specific quantitative comparisons of GE HealthCare's financial performance or product offerings against these named competitors or global benchmarks. Therefore, a direct assessment of results in the context of specific comparable companies, projects, and results is not possible based solely on the provided text.

Management Changes

Corporate Governance

Legal Proceedings

• A complaint was brought in the U.S. District Court for the District of Columbia against GE HealthCare and affiliates, alleging violations of the U.S. Anti-Terrorism Act through sales practices with the Iraqi Ministry of Health. The D.C. Circuit reversed the District Court's dismissal and remanded the case for further proceedings on January 23, 2026.

Related Party Transactions

• GE HealthCare continues to consider General Electric Company (GE) a related party due to board member affiliation following the Spin-Off on January 3, 2023.
• The company has a Transition Services Agreement with GE, under which net costs incurred were $172 million in 2024 and $372 million in 2023, primarily for IT, HR, supply chain, finance, and facilities services.
• A Tax Matters Agreement governs tax-related rights and obligations between GE HealthCare and GE, including indemnification for certain pre-Spin-Off tax obligations.
• A Trademark License Agreement grants GE HealthCare a license to use specified GE trademarks, including the GE Monogram and GE HealthCare word mark.
• Certain executive officers and directors own equity interests in both GE HealthCare and GE, creating potential conflicts of interest.

Stakeholder Impact

• Shareholders: Benefit from increased revenues, net income, and EPS, as well as the share repurchase program. Face risks from geopolitical instability, market competition, and potential tax liabilities related to the Spin-Off. The certificate of incorporation includes provisions that may discourage takeovers and limit stockholder power.
• Employees: Impacted by restructuring activities (workforce reductions), but also benefit from share-based compensation plans and the company's focus on health, safety, and culture. Subject to the Securities Trading Policy.
• Customers: Benefit from new product introductions, AI-enabled solutions, and expanded service offerings. Face potential impacts from supply chain disruptions, product quality issues, and changes in reimbursement policies.
• Suppliers: Subject to rigorous operating standards and potential impacts from supply chain disruptions and price fluctuations of raw materials.
• Creditors: Affected by the company's increased indebtedness and its ability to meet debt obligations, which is supported by strong cash flows and access to credit facilities.
• Patients: Directly impacted by the safety, quality, and efficacy of medical devices and pharmaceutical products, with potential risks from product liability claims or misdiagnoses. Benefit from advancements in medical technology and diagnostics.

Next Steps

• Close the acquisition of Intelerad, expected in the first half of 2026.
• Hold the Annual Meeting of Stockholders on May 7, 2026.
• Make approximately $350 million in total cash contributions to postretirement benefit plans in 2026.
• Amortize $108 million of net actuarial gain and $93 million of prior service credit from AOCI into Non-operating benefit (income) cost in 2026.
• Incur approximately $53 million in additional expenses related to restructuring initiatives, primarily over the next 12 months.
• Continue to apply for licenses to supply customers and support business in Russia, as required.
• Monitor developments in the China market, including increased competition and Volume Based Procurement policies.
• Evaluate the effect of ASU 2025-06 on financial statements, with an effective date for annual reporting periods beginning after December 15, 2027.
• Prepare for increased disclosures in notes to financial statements upon adoption of ASU 2024-03, effective for fiscal years beginning after December 15, 2026.

Key Dates

Recommendation

GE HealthCare demonstrates solid financial performance with revenue and earnings growth, supported by strategic acquisitions and a strong liquidity position. However, the company faces significant headwinds from tariffs, a declining PCS segment, and ongoing geopolitical uncertainties. While the long-term outlook for its AI and digital health investments is promising, these are highly competitive areas with execution risks. The increased debt load and substantial postretirement liabilities also warrant caution. Given the mixed financial signals and external challenges, a 'hold' recommendation is appropriate, suggesting investors monitor the company's ability to mitigate tariff impacts, revitalize the PCS segment, and successfully integrate new acquisitions while navigating the complex regulatory and competitive landscape.

Keywords

Healthcare Technology, Medical Devices, Pharmaceutical Diagnostics, AI Solutions, Cloud Computing, SEC Filing, 10-K, Financial Results, Revenue Growth, Operating Income, EPS, Acquisitions, Share Repurchase, Debt, Supply Chain, Cybersecurity, Regulatory Compliance, Risk Management, Corporate Governance, Sustainability